EA201490960A1 - Состав 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамид с немедленным высвобождением - Google Patents

Состав 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамид с немедленным высвобождением

Info

Publication number
EA201490960A1
EA201490960A1 EA201490960A EA201490960A EA201490960A1 EA 201490960 A1 EA201490960 A1 EA 201490960A1 EA 201490960 A EA201490960 A EA 201490960A EA 201490960 A EA201490960 A EA 201490960A EA 201490960 A1 EA201490960 A1 EA 201490960A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
benzamide
imidazol
pyrimidinyl
amino
Prior art date
Application number
EA201490960A
Other languages
English (en)
Russian (ru)
Inventor
Упкар Бхардвадж
Мангеш Садашив Бордавекар
Энн Риз Комфорт
Пин Ли
Шоуфэн Ли
Алексей Макаров
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201490960A1 publication Critical patent/EA201490960A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201490960A 2011-11-14 2012-11-12 Состав 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамид с немедленным высвобождением EA201490960A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14
PCT/US2012/064610 WO2013074432A1 (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Publications (1)

Publication Number Publication Date
EA201490960A1 true EA201490960A1 (ru) 2014-08-29

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490960A EA201490960A1 (ru) 2011-11-14 2012-11-12 Состав 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамид с немедленным высвобождением

Country Status (23)

Country Link
EP (1) EP2779995A1 (enExample)
JP (1) JP6275645B2 (enExample)
KR (1) KR20140093230A (enExample)
CN (1) CN103930094A (enExample)
AR (1) AR088844A1 (enExample)
BR (1) BR112014011518A2 (enExample)
CA (1) CA2855503A1 (enExample)
CL (1) CL2014001247A1 (enExample)
CO (1) CO6960546A2 (enExample)
EA (1) EA201490960A1 (enExample)
GT (1) GT201400094A (enExample)
HK (1) HK1197025A1 (enExample)
IL (1) IL232480A0 (enExample)
IN (1) IN2014DN03416A (enExample)
MA (1) MA35636B1 (enExample)
MX (1) MX2014005874A (enExample)
PE (1) PE20141337A1 (enExample)
PH (1) PH12014501062B1 (enExample)
SG (2) SG10201707768RA (enExample)
TN (1) TN2014000177A1 (enExample)
TW (1) TWI574690B (enExample)
WO (1) WO2013074432A1 (enExample)
ZA (1) ZA201402756B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
JP7776274B2 (ja) * 2021-07-19 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法
JP7776275B2 (ja) * 2021-07-26 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (enExample) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
KR20140093230A (ko) 2014-07-25
GT201400094A (es) 2017-09-28
CN103930094A (zh) 2014-07-16
CA2855503A1 (en) 2013-05-23
MA35636B1 (fr) 2014-11-01
CO6960546A2 (es) 2014-05-30
JP6275645B2 (ja) 2018-02-07
PH12014501062A1 (en) 2014-06-23
CL2014001247A1 (es) 2014-10-17
EP2779995A1 (en) 2014-09-24
IN2014DN03416A (enExample) 2015-06-26
AU2012339829A1 (en) 2014-05-29
SG10201707768RA (en) 2017-10-30
IL232480A0 (en) 2014-06-30
PE20141337A1 (es) 2014-10-16
WO2013074432A1 (en) 2013-05-23
BR112014011518A2 (pt) 2017-05-16
TW201325594A (zh) 2013-07-01
PH12014501062B1 (en) 2018-04-20
AU2012339829B2 (en) 2016-05-12
SG11201401476TA (en) 2014-10-30
HK1197025A1 (en) 2015-01-02
ZA201402756B (en) 2015-04-29
NZ623844A (en) 2016-09-30
AR088844A1 (es) 2014-07-10
TWI574690B (zh) 2017-03-21
JP2014533283A (ja) 2014-12-11
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
AR086913A1 (es) 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
PH12014501277A1 (en) Kinase inhibitors
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
PH12014501278A1 (en) Kinase inhibitors
PH12017502252A1 (en) Stable pharmaceutical composition for oral administration
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
PH12017501832A1 (en) Stabilized pharmaceutical composition
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
NZ597864A (en) Methods and compositions for treating leukemia
WO2013120852A4 (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo
TH148311A (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์
TH152470A (th) สูตรตำรับ 4-เมธิล-3-[[4-(3-ไพริดินิล-2-ไพริมิดินิลอะมิโน1-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟลูออโรเมธิล)ฟีนิล] เบนซาไมด์ชนิดปลดปล่อยทันที
HK1193102A (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
TN2014000218A1 (en) Kinase inhibitors
CL2010000211A1 (es) Formas cristalinas de sal clorhidrato 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil fenil]-3-4-piridin-3-il-pirimidin-2-ilamino)-benzamida; composicion farmaceutica que las comprende; utiles para tratar enfermedades que responden a la inhibicion de proteina quinasa.
IN2013CH00918A (enExample)